125 related articles for article (PubMed ID: 15981668)
1. PET and cancer screening.
Yasuda S; Ide M
Ann Nucl Med; 2005 May; 19(3):167-77. PubMed ID: 15981668
[TBL] [Abstract][Full Text] [Related]
2. Cancer screening with FDG-PET.
Ide M
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):23-7. PubMed ID: 16557201
[TBL] [Abstract][Full Text] [Related]
3. Cancer screening with whole-body PET/CT for healthy asymptomatic people in Japan: re-evaluation of its test validity and radiation exposure.
Ghotbi N; Iwanaga M; Ohtsuru A; Ogawa Y; Yamashita S
Asian Pac J Cancer Prev; 2007; 8(1):93-7. PubMed ID: 17477780
[TBL] [Abstract][Full Text] [Related]
4. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey.
Minamimoto R; Senda M; Uno K; Jinnouchi S; Iinuma T; Ito K; Okuyama C; Oguchi K; Kawamoto M; Suzuki Y; Tsukamoto E; Terauchi T; Nakashima R; Nishio M; Nishizawa S; Fukuda H; Yoshida T; Inoue T
Ann Nucl Med; 2007 Nov; 21(9):481-98. PubMed ID: 18030580
[TBL] [Abstract][Full Text] [Related]
5. Performance of 18-fluoro-2-deoxyglucose positron emission tomography for esophageal cancer screening.
Sekiguchi M; Terauchi T; Kakugawa Y; Shimada N; Saito Y; Matsuda T
World J Gastroenterol; 2017 Apr; 23(15):2743-2749. PubMed ID: 28487611
[TBL] [Abstract][Full Text] [Related]
6. Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device.
Kaida H; Ishibashi M; Fujii T; Kurata S; Ogo E; Tanaka M; Hayabuchi N
Ann Nucl Med; 2008 Feb; 22(2):95-101. PubMed ID: 18311533
[TBL] [Abstract][Full Text] [Related]
7. Is whole-body FDG-PET valuable for health screening? For.
Ide M; Suzuki Y
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):339-41. PubMed ID: 15726352
[No Abstract] [Full Text] [Related]
8. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report.
Terauchi T; Murano T; Daisaki H; Kanou D; Shoda H; Kakinuma R; Hamashima C; Moriyama N; Kakizoe T
Ann Nucl Med; 2008 Jun; 22(5):379-85. PubMed ID: 18600415
[TBL] [Abstract][Full Text] [Related]
9. Cancer screening of healthy volunteers using whole-body 18F-FDG-PET scans: The Nishidai clinic study.
Kojima S; Zhou B; Teramukai S; Hara A; Kosaka N; Matsuo Y; Suzuki H; Torigoe S; Suzuki T; Uno K; Fukushima M
Eur J Cancer; 2007 Aug; 43(12):1842-8. PubMed ID: 17614273
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. Detection of thyroid cancer by an FDG-PET cancer screening program: a Japanese nation-wide survey.
Minamimoto R; Senda M; Jinnouchi S; Terauchi T; Yoshida T; Inoue T
Anticancer Res; 2014 Aug; 34(8):4439-45. PubMed ID: 25075083
[TBL] [Abstract][Full Text] [Related]
12. Advantages and limitations of FDG PET in the follow-up of breast cancer.
Lind P; Igerc I; Beyer T; Reinprecht P; Hausegger K
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S125-34. PubMed ID: 15085295
[TBL] [Abstract][Full Text] [Related]
13. Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey.
Minamimoto R; Senda M; Terauchi T; Jinnouchi S; Inoue T; Iinuma T; Inoue T; Ito K; Iwata H; Uno K; Oku S; Oguchi K; Tsukamoto E; Nakashima R; Nishizawa S; Fukuda H; Murano T; Yoshida T
Ann Nucl Med; 2011 Jan; 25(1):45-54. PubMed ID: 20953985
[TBL] [Abstract][Full Text] [Related]
14. Application of PET and PEt/CT imaging for cancer screening.
Chen YK; Ding HJ; Su CT; Shen YY; Chen LK; Liao AC; Hung TZ; Hu FL; Kao CH
Anticancer Res; 2004; 24(6):4103-8. PubMed ID: 15736459
[TBL] [Abstract][Full Text] [Related]
15. Diffuse and diffuse-plus-focal uptake in the thyroid gland identified by using FDG-PET: prevalence of thyroid cancer and Hashimoto's thyroiditis.
Kurata S; Ishibashi M; Hiromatsu Y; Kaida H; Miyake I; Uchida M; Hayabuchi N
Ann Nucl Med; 2007 Aug; 21(6):325-30. PubMed ID: 17705011
[TBL] [Abstract][Full Text] [Related]
16. Application of positron emission tomography imaging to cancer screening.
Yasuda S; Ide M; Fujii H; Nakahara T; Mochizuki Y; Takahashi W; Shohtsu A
Br J Cancer; 2000 Dec; 83(12):1607-11. PubMed ID: 11104553
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET for axillary lymph node staging in primary breast cancer.
Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
[TBL] [Abstract][Full Text] [Related]
18. Detection of breast cancer in an FDG-PET cancer screening program: results of a nationwide Japanese survey.
Minamimoto R; Senda M; Jinnouchi S; Terauchi T; Yoshida T; Inoue T
Clin Breast Cancer; 2015 Apr; 15(2):e139-46. PubMed ID: 25454690
[TBL] [Abstract][Full Text] [Related]
19. [Current situation and problems of PET examinations].
Chihara H; Uozumi H
Nihon Hoshasen Gijutsu Gakkai Zasshi; 2005 Jun; 61(6):861-7. PubMed ID: 15995618
[TBL] [Abstract][Full Text] [Related]
20. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
